Live
- Tigress ‘Zeenat’ released into wild in Similipal
- Winning bypolls does not mean Karnataka govt is scam-free: BJP
- SIT and CBI Investigate Adulterated Ghee in Srivari Laddu Prasadam
- 'Hum Honge Kamyaab': MP's social awareness campaign for women's safety
- Kavitha demands Congress govt to implement Kamareddy Declaration on Backward Classes
- Why Switching to Bluesky is Best Move for Your Social Media Experience
- Telangana Rejects Rs.100 Crore Donation from Adani Group: CM Revanth Reddy
- MUDA case: Petitioner claims Lokayukta officers shielding accused
- IPL 2025 Auction: Pant was always in our bucket list, says LSG's Shashwat Goenka
- Andhra Pradesh's Bold New Strategy to Fix Highways Forever
Bharat Biotech's Rotavac 5D receives WHO prequalification
M Venkaiah naidu and Bharat Biotech's Joint Managing Director Suchitra Ella (Photo/IANS)
Bharat Biotech on Monday announced that the World Health Organisation (WHO) has awarded prequalification to its rotavirus vaccine, Rotavac 5D.
Hyderabad: Bharat Biotech on Monday announced that the World Health Organisation (WHO) has awarded prequalification to its rotavirus vaccine, Rotavac 5D.
The new variant of Rotavac is a unique rotavirus vaccine formulation that can be administered without a buffer. Its low dose volume (0.5 ml) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination. It is used for the prevention of rotavirus infection, which is prevalent in infants and young children.
WHO prequalification enables the procurement of Rotavac 5D by UN agencies, namely UNICEF and PAHO. It is a validation of the global quality and safety standards required for paediatric vaccines. WHO prequalification of Rotavac 5D will fast-track global access to this life-saving vaccine, the Hyderabad-based company said.
"Rotavac and Rotavac 5D are projects conceived, innovated, and executed in India; in collaboration with Indian and global partners. This is the culmination of a 30 year effort to develop a novel rotavirus vaccine, resulting in a major advancement in rotavirus disease prevention and reasserts India's leadership in developing and introducing rotavirus vaccines for the world. Today's announcement is an important step to further strengthen and fulfil Bharat Biotech's vision to address neglected diseases and prevent infections that continue to affect millions in the developing world," Bharat Biotech's Joint Managing Director Suchitra Ella said.
Bharat Biotech developed the first generation, rotavirus vaccine, Rotavac under a public-private partnership with the Department of Biotechnology, and 16 other international partners, making it the largest ever social innovation project for public health.
In the developing world, Rotavac has been instrumental in addressing deaths due to rotavirus, the leading cause of severe diarrhoea among children less than five years of age around the world, resulting in more than 200,000 deaths and 2 million hospitalisations worldwide. Vaccinations are an important part of global public health efforts to meet the Sustainable Developmental Goals of UNDP.
Bharat Biotech has so far supplied more than 250 million doses of Rotavac.
